Podcasts about Burstein

Dans cet épisode, Romain Giop explique en détail les mécanismes en jeu lors des principales douleurs attribuées aux migraines. Il évoque comment traduire la littérature en pratique, quelle place attribuer à la thérapie manuelle, et prodigue quelques conseils utiles aux patients souffrant de migraines, notamment en termes d'activité physique. Extraits sonores Fais pas ci, fais pas ça | Interprété par Jacques Dutronc | Ecrit par Jacques Lanzmann et Anne Segalen | Album : il est cinq heures | 1968 References Watson, D. H. & Drummond, P. D. The Role of the Trigemino Cervical Complex in Chronic Whiplash Associated Headache: A Cross Sectional Study. Headache: J. Head Face Pain 56, 961–975 (2016) Luedtke, K. & May, A. Stratifying migraine patients based on dynamic pain provocation over the upper cervical spine. J. Headache Pain 18, 97 (2017) Burstein, R., Noseda, R. & Borsook, D. Migraine: Multiple Processes, Complex Pathophysiology. J. Neurosci. 35, 6619–6629 (2015) Carvalho, G. F. et al. Physical therapy and migraine: musculoskeletal and balance dysfunctions and their relevance for clinical practice. Braz. J. Phys. Ther. 24, 306–317 (2020) Luedtke, K., Starke, W. & May, A. Musculoskeletal dysfunction in migraine patients. Cephalalgia 38, 865–875 (2017) Soutenez-nous sur Tipeee !

We start off the reign of Antiochus III reviewing just how bad a situation the empire finds itself in. Not only have we seen the edges fall away, but now cronies are squabbling over how to squander the remainder... Sources for this episode: Bevan, E. R. (1902), The House of Seleucus (Vol. I). London: Edward Arthur. Burstein, S. (2022), Ptolemy III Euergetes ("Benefactor") I, king of Egypt, early 246 to 221 BCE. In: Oxford Classical Dictionary. The Editors, Encyclopedia Britannica (2024), Ptolemy IV Philopator (online) (Accessed 29/04/2024). Author unknown, Wikipedia (date unknown), Antiochus III the Great (online) (Accessed 22/04/2024). Author unknown, Wikipedia (date unknown), Molon (online) (Accessed 29/04/2024). Author unknown, Wikipedia (date unknown), Ptolemy III Euergetes (online) (Accessed 29/04/2024). Author unknown, Wikipedia (date unknown), Ptolemy IV Philopator (online) (Accessed 29/04/2024).

Dementia can lead to a host of cognitive challenges, including disorientation and confusion. Among these symptoms, delusions—false beliefs that are strongly held despite evidence to the contrary—are particularly distressing for both the person diagnosed and their loved ones. We welcome Dr. Alvin Burstein, a psychiatrist renowned for his work in dementia care and mental health, to help us explore the complex interplay between dementia and delusions. Whether you're a caregiver, a family member, or simply curious about the intersections of mental health and cognitive disorders, this episode promises to provide valuable perspectives and practical advice. 

Power Man, Iron Fist and Misty Knight head to Seagate Prison to rescue Claire Temple and Doctor Burstein. When Luke Cage confronts Bushmaster, the results are explosive! Issue Covered: Power Man Volume 1, #49.

La noche del 4 de abril de 1950 Natalio Burstein, un conocido publicista, político y aventurero de fama internacional, se dio un tiro en la sien.El publicista ruso-argentino había entrado al país sin documentación, era objeto de investigación por parte de la Secretaría de Gobernación; había órdenes expresas de esa institución para localizarlo.Los agentes lo invitaron a que los siguiera. Burstein no opuso resistencia. Natalio y los agentes subieron a un carro patrulla. Burstein permanecía aparentemente sereno. No pronunció una sola palabra, pero poco antes de llegar a la jefatura de policía llevó rápidamente la mano al bolsillo trasero del pantalón y sacando una pequeña pistola “destroyer”, la aplicó a su sien derecha y apretó el gatillo.Puedes conocer más de este y otros casos en los Archivos secretos de La Prensa. Hosted on Acast. See acast.com/privacy for more information.

Denise Beady was 37 years old when she was diagnosed with early-stage breastcancer in 2017. She sought out care at Dana-Farber, in part because she was soyoung at the time of her diagnosis. In 2022, Denise felt another lump under her arm, and after tests and scans, it was revealed that Denise was having a recurrence of her breast cancer and it returned as stage 4 Denise works as a paramedic and dispatcher. When she's not working, she enjoysspending time with her husband Robert, and her two boys Tyler, 14, and Ryan, 11. She spends a lot of time driving them to different sports activities. Both of her kids do obstacle training at a gym in Weymouth. Her oldest runs cross country and her younger son plays soccer. Dr. Burstein is one of the world's leading experts in the multi-disciplinary and medical management of early- and late-stage breast cancer. Dr. Burstein has led or participated in innumerable clinical trials for breast cancer, including Phase 1, 2 and 3 studies of novel agents, biological treatments, chemotherapy, hormonal therapy, multi-disciplinary care, and quality of life. He writes widely on management of breast cancer, and his publications can be found in the New England Journal of Medicine, the Journal of Clinical Oncology, JAMA, and other leading medical journals.

This was initially intended to be a bonus episode but with Emily and I navigating various personal things we've decided to make this an official episode and it's a good one! Director Nanette Burstein joins us to discuss her new feature, Elizabeth Taylor: The Lost Tapes. We discuss Elizabeth Taylor's fame, the rumors that continue to swirl about her, and what she might hold in common with Robert Evans! This episode was created thanks to our Patrons: Ali Moore Amy Hart Danny David Floyd Donna Hill Gates Jacob Haller Jonathan Watkins McF Rachel Clark Shawn Goodreau A Button Called Smalls BadGuyRants Chris McKay Debbi Lynne Jeffrey Joseph Kayla Ewing Peter Blitstein Peter Bryant Peter Dawson Susannah Burger Brittany Brock Cat Cooper Daniel Tafoya David Baxter Diana Madden Emily Edwards Emily Frederichs Harry Holland Lucy Soles Nick Weerts Paul Rosa Tammy Sara Folger

Von Michael Nikbakhsh. Ausgabe #94 führt erstmals in den Kulturbetrieb und da zu einem neuen Podcast aus dem Missing Link-Netzwerk. Dieser heißt "Bühneneingang - Kultur von innen" und er verspricht einen unverstellten Blick hinter die Kulissen einer Branche, die gerade vom österreichischen Kulturjournalismus zu oft zu unkritisch beschrieben wird - das zumindest sagt der Host des Projekts, Fabian Burstein. Burstein ist Kulturmanager und Autor und er hat mich in eine seiner ersten Ausgaben eingeladen. Ein Gespräch. Die Dunkelkammer ist ein Stück Pressefreiheit.  Unabhängigen Journalismus kannst Du auf mehreren Wegen unterstützen:  Mit einem Premium-Abo bei Apple Podcasts https://shorturl.at/uDSTY Mit einer Mitgliedschaft bei Steady https://shorturl.at/guAD7 Mit einer direkten Spende https://shorturl.at/chJM8 Und ganz neu: Mit einem Merch-Artikel aus unserem Shop https://shorturl.at/uyB59   Vielen Dank! 

Academy Award-nominated Nanette Burstein's latest film ELIZABETH TAYLOR: THE LOST TAPES sees the director sifting through 40 hours of previously unheard interviews to build a portrait of actress and philanthropist Elizabeth Taylor using her own words. Taylor presents as a woman who suffers no fools, whether they be paparazzi demonizing her affair (and eventual marriage) to Eddie Fisher, journalists nagging her with questions about "sex symbol" status or critics quick to write her off as just a movie star and pretty face rather than an actress. I interviewed Burstein about the process of sifting through a day-and-a-half's worth of material, the unique serendipity of Taylor's presence at the film's visit to this year's Cannes Film Festival and how Taylor's legacy as an artist and philanthropist can impact others today. You can stream ELIZABETH TAYLOR: THE LOST TAPES on Max starting August 3rd. --- Follow The Movies on Twitter: @TheMovies_Pod End Music: "Super Ultra Graphic Modern Girl" - Chappell Roan

In this week's episode of [Your Podcast Name], we dive deep into a thought-provoking conversation with Dr. H David Burstein, a dentist and the author of the impactful book, Smartphones Don't Give Hugs. Dr. Burstein explores the critical issue of loneliness in our increasingly digital world, offering insightful strategies for those struggling with isolation. Through our discussion, we uncover how the constant connectivity of smartphones often masks a deeper emotional disconnect and discover practical ways to build genuine human connections. Join us as Dr. Burstein shares his expertise and personal anecdotes, shedding light on how we can bridge the gap between virtual interactions and meaningful, face-to-face relationships.

Cannabis sentiment is not positive enough. Given the challenges and fatigue, it's easy to lose sight of what's happening.Cannabis is being built from the ground up. Regulations and capital may currently hinder some aspects, but what's happening in the industry is undeniable.This week, we sit down with Ben Burstein, who reveals the actual situation in cannabis, focusing solely on information that tells the story through data.We discuss the following:Hemp BeveragesUnderstanding Market MaturityHow Upcoming Catalysts Influence the Next StepsAnd So Much MoreGuest Links:https://www.linkedin.com/in/benjaminburstein/https://www.leaflink.com/https://www.instagram.com/leaflink_/https://x.com/LeafLinkUS Follow us: Our Links.At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain The Dime is a top 5% most shared  global podcast The Dime is a top 50 Cannabis Podcast Sign up for our playbook here:

Cannabis sentiment is not positive enough. Given the challenges and fatigue, it's easy to lose sight of what's happening.Cannabis is being built from the ground up. Regulations and capital may currently hinder some aspects, but what's happening in the industry is undeniable.This week, we sit down with Ben Burstein, who reveals the actual situation in cannabis, focusing solely on information that tells the story through data.We discuss the following:Hemp BeveragesUnderstanding Market MaturityHow Upcoming Catalysts Influence the Next StepsAnd So Much MoreGuest Links:https://www.linkedin.com/in/benjaminburstein/https://www.leaflink.com/https://www.instagram.com/leaflink_/https://x.com/LeafLinkUS Follow us: Our Links.At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain The Dime is a top 5% most shared  global podcast The Dime is a top 50 Cannabis Podcast Sign up for our playbook here:

What has been happening in Israel and the wider Middle East over the past several weeks? What should you be looking for moving forward? We unpack all these questions and more with expert Alon Burstein!

Does knowing a lot of facts about the historical past – say, of early America – make us feel closer to it? Or is something else required? How can we–as my guest puts it, “appreciate a bit better what it felt like to be alive then. Naturally,” he continues  “we can't teach emotions to any who weren't alive to experience them how Pearl Harbor felt in real time – let alone Fort Sumter or Lincoln‘s assassination – is not transmissible. The historian can only do so much.“ But how to convey not merely the intellectual weight but the emotional burdens that humans once carried–and that we might no longer understand? My guest Andrew Burstein has done what he can to credibly bring early America closer to us in his new book Longing for Connection: Entangled Memories, and Emotional Loss in Early America. It is a work of history that is intricately plotted, connecting personalities and themes in a sort of great circular panopticon of early America, in which the reader sits at the orbital center of continual swirl and movement.   Andrew Burstein is the Charles Phelps Manship Emeritus Professor in the Department of History at Louisiana State University. Longing for Connection is the latest member of a large-and hopefully happy- family of books.   For Further Investigation You really should read some Alexander Pope. Find more about him, and some of his poems here. Poor Edward Everett. No one ever reads his Gettysburg address.  Some of the more closely related members of the Burstein family of books, many of them mentioned in the conversation, listed in order of publication: The Inner Jefferson: Portrait of a Grieving Optimist; Sentimental Democracy: The Evolution of America's Romantic Self-Image; The Original Knickerbocker: The Life of Washington Irving; and Lincoln Dreamt He Died: The Midnight Visions of Remarkable Americans from Colonial Times to Freud For an intro to cultural history, you should listen to Episode 32 Past episodes with a connection to this one are Episode 163: The First Martyr of the American Revolution; and Episode 344: Founding Scoundrels

On this episode of Deal by Deal, co-hosts Jason Griffith and Trey Andrews welcome Jonny Miller and Mario Burstein of Platt Park Capital Partners to discuss their emergence into independent sponsorship.Tune in as Jonny and Mario discuss how Platt Park came to be, how they secured their first deal, and how they can apply what they learned in their first deal to future deals. Jonny and Mario talk about managing seller expectations, focusing on the process instead of aiming for perfection, and how to make the transition from an acquisition to running the day-to-day operations of an acquired company.Connect and Learn More☑️ Jonny Miller | LinkedIn☑️ Mario Burstein | LinkedIn☑️ Platt Park Capital Partners☑️ McGuireWoods | LinkedIn | Facebook | Instagram | Twitter/X☑️ Subscribe Apple Podcasts | Spotify | Amazon MusicThis podcast was recorded and is being made available by McGuireWoods for informational purposes only. By accessing this podcast, you acknowledge that McGuireWoods makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in the podcast. The views, information, or opinions expressed during this podcast series are solely those of the individuals involved and do not necessarily reflect those of McGuireWoods. This podcast should not be used as a substitute for competent legal advice from a licensed professional attorney in your state and should not be construed as an offer to make or consider any investment or course of action.

3 big ideas discussed in this episode:  BIG IDEA #1: ValueFLOW - Visualize the customer value streams and internal processes that essential to your organizations success. Measure the flow of value through those systems and improve them, incrementally. BIG IDEA #2: StrategyFLOW - Adaptive leadership techniques that simplify vision casting, gain and maintain alignment and make the pivotal moves from strategy to tactics. BIG IDEA #3: Nested WorkFLOW - a nested framework for managing the flow of strategic requests down to the delivery teams and the flow of value back up to the customer. Get the show notes for this episode here: https://AskJeremyJones.com/357 Enjoy the interview   

June 18, 2024 | Fisker bankruptcy; journalist Laura Burstein on EyesOn Design by Automotive News

The director of a new archival film about Elizabeth Taylor called "Elizabeth Taylor: The Lost Tapes", Nanette Burstein makes her first appearance on the podcast. Also, club entreprenuer, Lon Ballinger discusses his years owning Webster Hall in NYC.

What is an emotional history? What of the “emotional history” of the United States? This is what historian Andrew Burstein investigates—and answers— in his latest book, Longing for Connection: Entangled Memories and Emotional Loss in Early America. The book covers the period from America's founding through the Civil War.

Rome's first and arguably greatest Emperor Octavian (Augustus) helped to evolve and expand the Roman Republic into an empire that encompassed France, parts of Germany, Asia Minor, Egypt and North Africa. But the seemingly all conquering Roman met his match in an African woman called Candace. Who was she? How did she come to be the de facto leader of the Kushites? How was she able to defeat Augustus and ensure an independence for her people that lasted for hundreds of years? In this episode, I speak with a subject matter expert Prof. Emeritus Stanley Burstein of California State University, Los Angeles. We discuss the Roman expansion into Africa, the identity of Kandake AKA "Candace," her legacy, and her huge role in shaping both African and Roman history.  Guest: Prof. Stanley Burstein works on Amazon Music: Pixabay This episode is sponsored by World History Encyclopedia, one of the top history websites on the internet. I love the fact that they're not a Wiki: Every article they publish is reviewed by their editorial team, not only for being accurate but also for being interesting to read. The website is run as a non-profit organization, so you won't be bombarded by annoying ads and it's completely free. It's a great site, and don't just take my word for it they've been recommended by many academic institutions including Oxford University. Go check them out at WorldHistory.org or follow this link: World History Encyclopedia.

April 10, 2024 | Laura Burstein talks EV design, Buick's new look; GM rethinks marketing by Automotive News

Dr. Angela DeMichele, Dr. Lynn Henry, and Dr. Harold Burstein present the latest breast cancer rapid recommendation update impacting two ASCO guidelines. This update focuses on the new option, capivasertib plus fulvestrant, for patients with hormone receptor-positive, HER2-negative metastatic breast cancer with activating PIK3CA or AKT1 mutations or inactivating alterations in PTEN based on data from the recent CAPItello-291 trial. They discuss the updated recommendations on lines of endocrine treatment and selecting between the options for patients with activating PIK3CA mutations. Additionally, we discuss implications for clinicians and patients, and what ongoing research is occurring in the field. Read the latest update, “Endocrine and Targeted Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer – Capivasertib-Fulvestrant: ASCO Rapid Guideline Update“ at www.asco.org/breast-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/breast-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.24.00248 Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.   My name is Brittany Harvey, and today I am interviewing Dr. Harold Burstein from Dana-Farber Cancer Institute, Dr. Angela DeMichele from the University of Pennsylvania, and Dr. Lynn Henry from the University of Michigan, co-chairs on “Endocrine and Targeted Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Capivasertib–Fulvestrant: ASCO Rapid Guideline Update.” Thank you for being here, Dr. Burstein, Dr. DeMichele, and Dr. Henry. Dr. Harold Burstein: We're happy to be here.  Brittany Harvey: And before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including our guests on this episode today, are available online with the publication of the guideline update in the Journal of Clinical Oncology, which is linked in the show notes.  So then, to kick us off, Dr. Burstein, could you first describe what prompted this rapid update, which provides updated recommendations for two ASCO guidelines: the biomarkers for systemic therapy in metastatic breast cancer guideline, and the endocrine treatment and targeted therapy for hormone receptor-positive, HER2-negative metastatic breast cancer guideline? Dr. Harold Burstein: Thanks, Brittany. Well, this team has been working, as you mentioned, actually, on two guidelines, which are clearly evolving in parallel and kind of converging, actually, when you look at data, as we'll be talking about in the next few minutes. The particular catalyst here was a large randomized clinical trial which looked at a new targeted therapy in the space of estrogen receptor-positive, HER2-negative breast cancer. That drug is capivasertib. And the trial was the so-called CAPItello study. In that trial, patients who were receiving second-line therapy with fulvestrant were randomized to that treatment alone, or that plus capivasertib. So the data from that study were the first strong signal that we needed to update the guideline because they were important clinical data.   The other strong signal was that the drug was tested in a cohort of patients who had a specific set of mutations in their cancers. And that included PIK3CA mutations, a class of mutations for which we already had a targeted drug. But it also included some new potential targets, including mutations in the AKT gene itself, capivasertib is an AKT inhibitor, as well as loss of PTEN protein functionality, which potentially sensitizes tumors to the targeted action of this drug as well. So while we had a couple of guidelines catching up on the endocrine therapy space, which is increasingly looking like a targeted therapy space, it was clear that this major study, which had clinical and diagnostic implications, would sort of push them together and served as the impetus for updating both guidelines at the same time. Brittany Harvey: Understood. I appreciate that background information.   So then, Dr. DeMichele, based on this updated data that Dr. Burstein just described, what is the updated recommendation from the guideline panel regarding lines of endocrine treatment? Dr. Angela DeMichele: Well, I think this is where the biomarker evolution that Dr. Burstein just referred to really comes in because now we have the opportunity to perform genomic testing in patients who have ER-positive, HER2-negative metastatic breast cancer, on either the tumor or commonly from the blood. And we can now start to tailor treatment to the specific genomic abnormalities that that patient's tumor contains. So now our guideline really marries both the genomic abnormality with the therapeutic option. First-line treatment remains endocrine therapy plus a CDK 4/6 inhibitor. But things then really start to diverge once we enter second and third-line therapy because at that point, we now have the option to test for several genomic markers: ESR1 mutations, PIK3CA mutations, AKT1 mutations, and PTEN inactivation. And based on whether the tumor has one or any of those mutations, we can then select the therapy based on that.  So in the case of capivasertib, as you just heard, that is a therapy for patients whose tumors have PIK3CA mutations or activating mutations in AKT1 or loss of PTEN. But other patients who don't have one of those mutations may, in the second line, go on to another drug. For example, if they have an ESR1 mutation, they then may be eligible to take elacestrant. Patients who have no targetable mutations still have a targeted option in that they can use everolimus. And in all of these settings, the endocrine therapy partner for this line of therapy is typically fulvestrant. So now we're really starting to tailor therapy in the second- and third-line based on genomic changes. Brittany Harvey: Excellent. That information is helpful for choosing optimal therapy tailored to the individual patients, as you just described.  So then, Dr. Henry, what guidance does the expert panel provide regarding choosing a PIK3CA targeted option? Dr. Lynn Henry: Thank you. So for patients whose tumors are found to have an activating mutation in PIK3CA, we now have two drug options: either alpelisib or capivasertib in combination with fulvestrant. And the problem is, these drugs have not been compared head-to-head. We can't say that one is clearly better than the other, either in terms of efficacy or in terms of side effect profile. What we do have is information from two separate trials in which they were each tested against placebo. The efficacy appears to be fairly similar based on the data that we have. It does appear that the side effect profiles may be slightly different. And so, when you have a patient sitting in front of you and you're trying to decide how best to treat her, you really have to think about, what symptoms does my patient already have? What is she more or less likely to tolerate? So what we do know is that it appears that the rates of grade 3 diarrhea and rash were slightly higher with capivasertib. It looks like hyperglycemia was higher with alpelisib, as was treatment discontinuation. So really you have to make an individualized decision when you have a patient sitting in front of you about which drug you'd like to try. Of course, if someone doesn't tolerate one drug, you can always switch to the other one.  Brittany Harvey: I appreciate that analysis and to provide guidance without a head-to-head trial and to specifically provide options based on an individual patient's profile.   So then, Dr. DeMichele, what should clinicians know as they implement these new recommendations?  Dr. Angela DeMichele: Well, first of all, I think most clinicians now are becoming more familiar with the procedures required for doing genomic testing. But this is something that now has become the standard of care. And so, it is incumbent upon all of us who treat these patients to understand what the options for genomic testing are for that patient, which companies offer this testing, how to send a sample, and how to interpret the report that comes back. So, I think this has really added a level of complexity to the therapy for patients. I also think that one can't simply apply an algorithm to a patient. We have to really treat the whole patient and we have to take into consideration, as Dr. Henry said, the toxicities of these agents and the cost which is also a major issue. So I think that while it is more complex, really that doctor-patient relationship is so important in communicating what these genomic tests mean for a patient and for their options, and also important for the clinician to really understand what the different therapeutic agents might mean for a patient, and really try to pick the agent that's best for that patient. Using genomic testing is just one of several different features that they'll consider. Brittany Harvey: Absolutely. It's key to obtain the data needed to select appropriate patients and to recognize the complexity.   So then, Dr. Henry, in your view, how will this update impact patients with metastatic breast cancer? Dr. Lynn Henry: Yes, so as we've discussed, I think this is really exciting. Over the last few years, we have had quite a number of new medications that have become available for patients and have been FDA-approved. And so this is yet the latest in a series. For those patients whose tumors have a PIK3CA mutation, as we discussed, there are now two options. So you have a choice depending on which one is better covered by insurance, by which one you may tolerate better. But I think the other thing is now, although it's a smaller subset of patients, there are patients out there whose tumors have mutations in AKT1 or alterations in PTEN, and so there's an entirely new endocrine therapy-based option available for them that wasn't available before. So I think that thinking about the new data that are out there, the new drugs that are out there, really is exciting because there are new options available and hopefully there are more to come as well.    Brittany Harvey: Absolutely. It's great to have these new options.  So, finally, Dr. Burstein, Dr. Henry just mentioned what's to come. Could you touch on what some of the outstanding questions are regarding endocrine therapy for patients with metastatic breast cancer?  Dr. Harold Burstein: A couple of things to say. First, ER-positive metastatic breast cancer is the most common kind of metastatic breast cancer, roughly three quarters of metastatic cases of breast cancer will be hormone receptor-positive cancers. So this is a very big public health issue around the world, actually, breast cancer being the number one most commonly diagnosed cancer of women around the world. So minor or major improvements in treatment for advanced ER-positive breast cancer really have a tremendous impact.  The second thing is it's been remarkable to see the progress in the past decade. We've gone from simply targeting the hormonal access itself with medicines like tamoxifen or aromatase inhibitors or an injectable selective estrogen receptor degrader like fulvestrant to incorporating targeted therapies at the same time. And this whole class of drugs called CDK4/6 inhibitors has emerged which we use in either first- or in second-line therapy. Those drugs have transformed our standard of care, improved survival for patients with advanced ER-positive disease, now with median survival nearly 50% longer than what we had seen in the past.  And if you've heard, we have a wealth of opportunities. We can target PIK3CA, we can target ESR1 mutations. Other drugs emerging in the space include PROTACs which is another way of degrading the estrogen receptor. And so there's going to be more progress in the years to come.   So one of the biggest challenges has been to try and understand, is there really an optimal way to use these drugs, or can we be smarter about the particular sequence of all these particular things that are happening.  So one example of this was a recent study that is on a drug, not as yet FDA-approved, called inavolisib, which is a PIK3CA targeted drug used in first line in combination with a CDK4/6 inhibitor and endocrine therapy. And that study, for a high-risk group of women with ER-positive metastatic disease, actually showed a dramatic improvement in overall survival, asking the question if combining some of these targeted therapies together might yet further improve outcomes.  And as you've heard from the diagnostic space, one of the other interesting things is that tumors evolve over time. And so acquisition of the estrogen receptor mutations, ESR1 mutations, which are typically not found early in the course of advanced breast cancer but otherwise later, now have targeted treatments. So there's a whole bunch of stuff going on all at the same time, including multiple ways of targeting things, serial testing to look for acquisition of ESR1 mutations and new pathways to explore. It's an embarrassment of riches in some respects because it has meant it's actually really hard to write a guideline as you've heard, which says, “Do this first, do this second, and do this third.” I suppose that's a good problem to have under the circumstances, but it's going to require really thoughtful clinical trials and careful analysis to help guide specific lines of treatment recommendations like that.  Brittany Harvey: Excellent. We'll look forward to these exciting, continuing developments for patients with metastatic breast cancer. And I want to thank you all so much for your work to develop this rapid recommendation update for these two guidelines. And thank you for taking the time on this podcast today. Dr. Harold Burstein: Thanks. Dr. Lynn Henry: Thank you so much.  Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/breast-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO guidelines app, available in the Apple App Store or the Google Play Store. If you have enjoyed what you heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

In this episode, Josh interviews Dr Harold Burstein. A graduate of Harvard University and Harvard Medical School, Dr Burstein's initial PhD was in cellular immunology. After receiving his oncology fellowship at the Dana Farber Cancer Institute, he joined the staff in 1999. Hal has a particular interest in breast cancer and has participated in national and international clinical trials while also working to develop treatment guidelines worldwide. A passionate educator, Dr. Burstein teaches medical students, residents and fellows at Harvard Medical School and the Dana Farber Cancer Institute.The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.The Kinghorn Cancer Centre: https://tkcc.org.au/Dana Farber Cancer Institute: https://www.dana-farber.org/For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow. Hosted on Acast. See acast.com/privacy for more information.

In discussion with Dr. Harold Burstein, we cover treatment algorithm of HER2+ breast cancer. We covered the current standard of care treatment options for HER2+ breast cancer.   #HER2 #Sensitive #Breast #Cancer #2024 #oncology #oncbrothers   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Alon Burstein is a Professor in Political Science at the University of California Irvine. He discusses the bloody history of Israel's and Hamas' birth. The historical backdrop between the two sides reveal the power dynamics at play today. Check out this episode on youtube: https://www.youtube.com/watch?v=If6LUKAecC8 As always I'm your host and lawyer: jasoningber.com.

In this episode I'm joined by Chanan Burstein. Chanan is a founder of Tzachi Israel, a non-profit 501(C)(3) organization that delivers supplies and equipment to Israeli troops. The goods delivered can range anywhere from toiletries to medical supplies and body armor. Please consider supporting our project by donating to us. Ways to donate and other resources here: ⁠⁠https://linktr.ee/analyzeeducate.⁠ Tzachi Israel: https://www.instagram.com/tzachi.israel/

Erie County Health Commissioner Dr. Gale Burstein on the death of a person who overdosed on carfentanil

Ben Burstein is LeafLink's Sr. Corporate Development Associate, helping manage industry research, mergers & acquisitions, and strategic partnerships for the company. He's been featured as an industry expert both on-air (ABC, FOX, NPR) and through digital channels (Forbes, Cannabis Business Times, MJBizDaily, St. Louis Business Journal). Prior to LeafLink, he worked at Citi Equity Research and Tuatara Capital. Ben is a graduate of the Wharton School of the University of Pennsylvania. =================== About Cannabinoid Connect Thought-provoking discussions, expert insights, and captivating stories shaping the future of this transformative industry. Subscribe and follow via the following platforms: Website Spotify Apple Podcasts YouTube X Instagram Facebook TikTok  

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Harold (Hal) Burstein is an internationally renowned breast cancer expert. In this episode, Hal discusses a broad range of topics related to breast cancer, starting with the intricacies of breast anatomy and the endocrinological factors at play. He covers the spectrum of breast cancer, from precancerous lesions to invasive breast cancer, classifying these conditions into a helpful framework. He delves into various screening methods, including self-exams, mammograms, ultrasounds, and MRIs, and addresses the ongoing debate surrounding early screening and detection. Hal provides insights into the latest advancements in cancer treatment, offering valuable guidance for individuals to understand their unique circumstances within the three primary categories of breast cancer. Finally, Hal delves into the role of genetics in breast cancer and brings attention to the less commonly addressed issue of male breast cancer. We discuss: The prevalence and mortality rate of breast cancer in women [4:15]; The anatomy of the breast and the complex factors behind breast cancer development [6:30]; The three main categories of breast cancer [16:45]; Breast cancer risk: the impact of menopause, estrogen, breast density, obesity, and more [21:15]; Finding and evaluating lumps in the breast [25:30]; Identifying and treating precancerous lesions like ductal carcinoma in situ (DCIS) [31:00]; Post-lumpectomy for DCIS: standard of care, future risk of cancer, and pros and cons of radiation and other preventative options [41:15]; Lobular carcinoma in situ (LCIS): how it differs from DCIS in terms of treatment and future risk of invasive cancer [55:00]; Breast cancer screening: mammography, ultrasound, MRI, and more [1:03:45]; Invasive breast cancer: pathology report, surgery, and survival [1:11:00]; The argument for aggressive screening for breast cancer [1:22:15]; Advances in the treatment of breast cancer, adjuvant therapy, and neoadjuvant therapy [1:27:00]; The use of hormone replacement therapy in women who are in remission from breast cancer [1:41:15]; The role of genetics in breast cancer [1:44:45]; The importance of multidisciplinary care delivered by cancer centers [1:53:15]; Breast cancer in men [2:03:30]; Parting thoughts and takeaways [2:05:45]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Daniel and Harry welcome filmmaker Nira Burstein to discuss "The Pawnbroker," a 1964 film directed by Sidney Lumet and starring Rod Steiger.They unpack the film's exploration of collective trauma and its consequences on the individual, consider the way the movie might be received by those more and less familiar with the Holocaust, and analyze how the film's trailblazing editing techniques heighten Sol's internal drama and put the audience in his head.Finally, they talk to Nira about her debut documentary feature, Charm Circle, now streaming on the Criterion Channel!As always, they close out the episode by ranking the film's "Jewishness" in terms of its cast & crew, content, and themes.The Pawnbroker TrailerImdb PageWatch Charm Circle on the Criterion ChannelNira Burstein on TwitterNira Burstein on instagramConnect with Jews on Film online:Instagram - https://www.instagram.com/jewsonfilm/Twitter - https://twitter.com/jewsonfilmpodYouTube - https://www.youtube.com/@jewsonfilmTikTok - https://www.tiktok.com/@jewsonfilmpod

Ben Burstein is LeafLink's Sr. Corporate Development Associate, helping manage industry research, mergers & acquisitions, and strategic partnerships for the company. He's been featured as an industry expert both on-air (ABC, FOX, NPR) and through digital channels (Forbes, Cannabis Business Times, MJBizDaily, St. Louis Business Journal). Prior to LeafLink, he worked at Citi Equity Research and Tuatara Capital. Ben is a graduate of the Wharton School of the University of Pennsylvania. =================== LeafLink is the wholesale cannabis industry's leading technology provider, offering commerce, financial, and logistics services that help improve the operations of brands, retailers and distributors. LeafLink is backed by leading venture capital firms and strategic investors and has raised more than $330 million of equity and equity-linked securities since its launch in 2016. Learn more at www.leaflink.com. =================== About Cannabinoid Connect Thought-provoking discussions, expert insights, and captivating stories shaping the future of this transformative industry. Subscribe and follow via the following platforms: Website Spotify Apple Podcasts YouTube X Instagram Facebook

Bartenders Sue Shuberts; Burstein, Kudrow, Hawke in Uhry Developmental Reading; One-Night Only ‘Glory Days’ Concert “Today on Broadway” is a daily, Monday through Friday, podcast hitting the top theatre headlines of the day. Any and all feedback is appreciated: Grace Aki: grace@broadwayradio.com | @ItsGraceAkiMatt Tamanini: matt@broadwayradio.com | @BWWMatt Patreon: BroadwayRadiohttps://www.patreon.com/broadwayradio read more The post Today on Broadway: Thursday, August 31, 2023 appeared first on BroadwayRadio.

This podcast is a commentary and does not contain any copyrighted material of the reference source. We strongly recommend accessing/buying the reference source at the same time. ■Reference Source https://www.ted.com/talks/julie_burstein_4_lessons_in_creativity ■Post on this topic (You can get FREE learning materials!) https://englist.me/156-academic-words-reference-from-julie-burstein-4-lessons-in-creativity-ted-talk/ ■Youtube Video https://youtu.be/0oNbxDVQuAI (All Words) https://youtu.be/kTgwP_rZDe0 (Advanced Words) https://youtu.be/lHCj2wOQk0Q (Quick Look) ■Top Page for Further Materials https://englist.me/ ■SNS (Please follow!)

This week on the podcast, we talk to Jay Burstein, a luthier in Vermont who makes guitars from industrial hemp. His company is called Hemptone Music and specializes in fine-crafted hemp instruments. On this episode, Burstein talks about his process of making the guitars and the journey he's undertaken to improve his production methods. Burstein was first on the podcast in early 2019. Back then he was using clay and fiberglass to make molds to shape the body of the instruments, but he's since streamlined his process and now uses a more elaborate method for shaping the bodies of the guitars. “Not only do you have to design the instrument, you have to come up with the tooling involved to make it,” he said. He worked with an engineer and a facility to mill the aluminum for the new body mold. He originally wanted to make a small but sturdy travel-sized guitar, after trekking through South America with a traditional guitar made from wood, which he said didn't hold up so well. “Basically the instrument I designed is the one I'd always wanted, as someone who'd done some traveling,” he said. Last month, Burstein loaned one of his hemp guitars to me for my trip to the Montana Summer Hemp Summit in Great Falls. The instrument traveled well and fit nicely in the overhead compartments of the airplane. “It's approximately half of the size of a guitar, but it's got a full 25-inch scale length, which is about the string length of a full-sized guitar,” Burstein said. “But I lop it off essentially at the fifth fret.” For guitar players, this would be like having a capo on the fifth fret. The guitar plays like any other guitar, but the low note is an A rather than an E. Taking the guitar to Montana was a homecoming of sorts, because Burstein sourced the hemp fibers for the instrument from IND Hemp in Montana. The small guitar made a big splash at the summit, where it was on display at the Lancaster Farming expo table. Summit attendees played it and marveled at its uniqueness. Everyone wanted to know the process of how it was made. Hear Jay Burstein from Hemptone Music explain his process:   Hemptone Music https://www.hemptonemusic.com/ Hemptone Music on Instagram: @hemptonemusic   Penn State's Ag Progress Days https://agsci.psu.edu/apd High Five, Miss America https://www.lancasterfarming.com/country-life/fairs-and-shows/high-five-miss-america/article_cae17c9d-54ba-512c-b734-cdd948873c39.html   Thanks to our Sponsors! IND HEMP https://indhemp.com/ King's Agriseeds https://kingsagriseeds.com/    

It's not uncommon to hear people talking about ‘unleashing the wild woman,' but the next question is - then what? On this episode of the It's All Me podcast, Gervase sits down with Mandy Burstein to discuss their journeys of finding safe and healthy ways to express generationally suppressed emotions, the healing experience of embracing the duality of death and grief, and what has been healing for them as mothers rewriting their own traumas and triggers while simultaneously being the blueprint for their children. Listen in for a behind the scenes look at the experiences provided at their previous retreat held in Sayulita, Mexico. Mandy Burstein is a teacher of yoga, mindfulness and transformational breathwork who is passionate about  lovingly pushing people beyond their comfort zones to discover how strong, beautiful and powerful they truly are. Since 2010, she has led group classes, spiritual self-discovery workshops and week-long yoga retreats, and was a guest teacher at Gervase's Sayulita retreat.   Want more of Mandy? Check her out here: MANDY BURSTEIN (@zengirlmandy) | Instagram Mandy Burstein | Website Doors closing on July 26th for  Higher—The Mastermind to help you set new standards and maintain a higher sense of Self Learn more and join: https://www.gervasekolmos.com/maintenance-mastermind VIP option to add two 1:1 sessions and Voxer coaching with G available Follow Gervase Connect with Gervase on Instagram: www.instagram.com/gervasekolmos Visit her website: Gervase Kolmos   *If you'd like to invite Gervase into your company to facilitate coaching or conversation to shift company culture, please email us at hi@gervasekolmos.com Resources and Related Episodes: Making our kids our excuse and using Covid as our Phoenix moment - It's All Me | Podcast on Spotify   Joy is a Really Good Reason - It's All Me | Podcast on Spotify    

Ben Burstein, Strategist, LeafLinkBen Burstein is LeafLink's Strategist, helping manage industry research, mergers & acquisitions, and strategic partnerships for the company. He's been featured as an industry expert both on-air (ABC, FOX, NPR) and through digital channels (Cannabis Business Times, MJBizDaily, St. Louis Business Journal, Santa Fe Reporter). Prior to LeafLink, he worked at Citi Equity Research and Tuatara Capital. Ben is a graduate of the Wharton School of the University of Pennsylvania.https://www.linkedin.com/in/benjaminburstein/https://www.instagram.com/leaflink_/?hl=enhttps://www.linkedin.com/company/leaflink/https://twitter.com/LeafLinkUS?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

Ben Burstein is LeafLink's Strategist, helping manage industry research, mergers & acquisitions, and strategic partnerships for the company. He's been featured as an industry expert both on-air (ABC, FOX, NPR) and through digital channels (Cannabis Business Times, MJBizDaily, St. Louis Business Journal, Santa Fe Reporter). Prior to LeafLink, Ben worked at Citi Equity Research and Tuatara Capital. Ben is a graduate of the Wharton School of the University of Pennsylvania.

Nira Burstein @nira.isanalog will show the opening of her debut doc feature Charm Circle May 2 @reunion @alamonyc. We talk a lot about Judaism in the arts, NYC, family, and the difference between narrative and doc work. Lotsa parent talk. I'm interested in what audiences will make of it next week. To me, a big topic we got into was how people identify with her parents as characters and their tendencies. We see them as very, very Jewish, but many others less familiar with this culture don't really think about it, and are they just neurotic? Anxious? Weird? Nira's been to a bunch of Reunion nights, so I'm happy to be able to showcase her work. Excited for everyone to see. https://reunion5223.splashthat.com/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/teawithsg/message Support this podcast: https://podcasters.spotify.com/pod/show/teawithsg/support

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

Frank Morano interviews Dr. H. David Burstein, the author of “Smartphones Don't Give Hugs: A Guide Out of Loneliness" about the loneliness epidemic and smartphones. Learn more about your ad choices. Visit megaphone.fm/adchoices

Matt and I met in high school and took note of each other as the only ones who could handle a power tool when it came time to build the theater sets.  Now years later we both are general contractors with very different specialties.

Suzy speaks to Joan Burstein, a.k.a. Mrs B of Browns, the legendary, groundbreaking boutique in South Molton Street, London, which Mrs B co-founded in 1970 with her late husband Sidney. Produced by Natasha Cowan @tashonfash Edited by Tim Thornton @timwthornton Music by @joergzuber Graphics by Paul Wallis To find Suzy's articles visit https://suzymenkes.com ...find Suzy on Instagram @suzymenkes and Twitter @thesuzymenkes Hosted on Acast. See acast.com/privacy for more information.

Political strategist and stand up comedian, Josh Burstein talks political experience and how comedy will can help the world.

While John McAfee sat in a Guatemalan detention cell, he made an exclusive deal with documentary producer Francois Garcia to tell his story. After his deportation to Miami, McAfee traveled the country worming his way back into the media spotlight, despite looming cartel paranoia. Garcia followed McAfee for several years producing a documentary series about McAfee's life with director Billy Corben, facing some typical challenges of "show business," along with strange interference by documentary filmmaker Nanette Burstein.

In this episode, Marcela Salmon speaks with Andy Burstein, founder of Accessible Pharmacy Services for the Blind, a home delivery pharmacy and health care company. Marcela expresses how excited she is to learn more about how Andy got started with the company, which is the largest, blind-owned healthcare company in the world, and the only provider of its kind. Andy explains how his business model merges accessibility and health care, and works with individuals on a personal basis providing personalized medication. By working with the individual, identifying specific challenges the company can then assemble a collection of solutions that empower individuals to lead more independent, and ultimately, healthier lives. Andy shares that he idea of the company started five years ago. At the time, Andy was running a healthcare marketing firm and he wanted to educate his clients on how to be more accessible and how to experience patient growth. Andy explains that he met another cofounder of Accessible Pharmacy, Alex, because their sons both played Little League baseball together. Alex, who is blind due to Retinites Pigmentosa, had earned a PhD; his dissertation focused on accessibility in the American retail space. Marcela asks how Andy became interested in accessibility to which Andy replies that he has been very aware of the “DEI space.” And that, as a consumer, parent, and member of society, he always tries to be inclusive, especially in the healthcare field. It was important for Andy to be able to answer questions to his clients and staff about ways to be more inclusive. Alex learned about the Americans with Disabilities Act, and about online accessibility and the inability of individuals to gain access to websites and information. He learned how blindness intersects with online accessibility. Andy explains that for individuals with low vision, screen readers are used to read the content of websites out loud, but not all websites are compatible with the screen readers. Andy continues, saying that if someone can't access a website, no matter the tools available to them, what would happen if someone couldn't read their medication? He then discusses how critical it is for people to be able to read the expiration dates and labeling on prescriptions. They also might not be able to understand the drug interactions or the time of the day, or how many refills are left and so on. While Andy discusses the layers upon layers of challenges, his company is learning every day how they can empower the individual to understand and manage their medication and do it in a way that reduces stress, time, and helps them live healthier lives. Andy says that then, he and Alex asked themselves the question, what would it be like if they created a pharmacy experience that was tailored towards individuals who are blind? After getting feedback on their business plan from many blind organizations, such as The National Federation for the Blind, the American Council for the Blind, the AFP, the ACB, The Foundation for Fighting Blindness, they realized there was indeed a real need for this in the marketplace. After a few months researching and learning the pharmacy industry they started to look for a partner who could help them realize the opportunity in the healthcare space, which led to their third business partner, Dr. Jason Becker. Jason had an existing business model, where he spent the first 25 years of his career focusing on patients with intellectual and cognitive disabilities, who more often than not lived in group homes. He helped his two partners, Andy and Alex, realize they need to focus on the individual. They realized the key was to have a conversation with a patient first. They need to learn as much as possible about them because they have a collection of high tech, low tech and different audio label solutions that can be provided. Once they get the information, the company will reach out to the prescribers to get feedback and then they contact the insurance company to confirm eligibility. Andy stresses how they also offer a concierge capacity, making the phone calls to the doctors or existing pharmacists on behalf of the patient. They will also be the main contact for the insurance company to confirm eligibility. For patients who are deaf blind, they have those conversations via text, and email. Their company mission is to eliminate barriers to communication and accessibility. So, they provide free home delivery, all the support and education for free as they make their money by being reimbursed by insurance companies to the patient. Marcela thanks Andy who then informs the listeners where to get more information. What We Discuss in this Episode 01:58 …Accessible Pharmacy Services for the blind. We're a home delivery pharmacy and health care company. And we focus on supporting patients who are blind, deaf blind, and have low vision. We're the only provider of its kind. We're the largest blind owned healthcare company in the country. 02:49 …Our whole model is about merging accessibility and health care and working with individuals on a personal basis. Personalized medication, identifying the individual, identifying what challenges they may already have with their existing medication with their diabetes, how they're currently managing it, and assembling a collection of solutions that empower them to live more independently, manage their own medication, manage their own diabetes, and ultimately live healthier lifestyles. 03:37 … Our goal was to reach back out to our clients and educate them on how they can be more accessible, to be able to expand their offering and their messages to their existing patients, and also to experience patient growth. I decided to reach out to friends and family and people I knew who either had familiarity with the disability world or had a disability themselves, who could give me insight into their experience. 07:45 …As a business person who was working in the healthcare field, it was important for me to be able to answer questions to my clients, and to my staff, about how we can be more inclusive. …So learning about the Americans with Disabilities Act, learning about online accessibility and the inability of individuals to gain access to websites and information, and learning about blindness in particular, and how it intersects with online accessibility. Individuals who are blind, the way that they use the internet is that they use an Assistive Technology called a screen reader…But for the most part, the screen reader is essentially a software that accesses websites and essentially reads the website out loud to the consumer. …One of the challenges that exists is that not all websites are compatible with screen readers. Through a combination of awareness through lawsuits, through the knowledge and growth of the industry, people are learning more and more about online accessibility. Individuals with low vision may use magnification, may use oversized monitors, may sit closer to the screen, and there are a lot of solutions to gain access to online accessibility. …Our goal as I mentioned, as a consumer, is to learn more about accessibility, but also to be able to create solutions for our clients in the healthcare space. 10:27 …If a website's not accessible, it doesn't make a difference what type of assistive or adaptive technology an individual has, or their desire to gain access to that information. They just can't access it. Now imagine taking that concept of a website and imagine applying that to medication. Someone has a pill bottle, and they don't know what the pill bottle is. They can't read the instructions. They don't know what the expiration date is. They don't know what the warnings are… The good news is we're learning more every day about how we can empower that individual to understand and manage their medication and do it in a way that reduces stress, reduces time, and helps them live healthier lives. 12:05 …We have a dynamic in our company. It's a living ecosystem. And every time we solve a challenge for a patient, because of their unique set of circumstances, we then learn that we can now say okay, here's a collection of solutions that we can apply to a similar individual with similar circumstances. …What would it be like if we created from the ground up a pharmacy experience that was tailored towards individuals who are blind? … No one was really providing an A to Z solution focused on identifying all the different challenges that may exist in medication matters. It validated for us that there's a need for this in the marketplace. 18:22 …We need to understand the individual. What is this person's cognitive issue? What's their intellectual issue? Is it deteriorating? Is there a caregiver in their home? Or, are they living in a facility? Are they a caregiver for someone else? Are they also a caregiver for a spouse? What's their level of sight?...How are they currently managing their medications?...A combination of those things can create unnecessary and unintended side effects that range from something problematic where a person is experiencing a side effect, or sometimes a combination of those things can impact the body's ability to absorb those medications and process those medications. Ultimately, they're not getting the benefit from those medications. …We also work in a concierge capacity. So we're the ones who will make the phone calls to the doctors and will make a phone call to the existing pharmacist to get feedback on behalf of the patient. We will call the insurance company to confirm eligibility and confirm that the copays are staying the same. That conversation more often than not happens on the telephone. For patients of ours who are deaf blind, we also have those conversations via text, and email. 23:56 …One of the questions we ask the individual when we have that initial conversation is what's the best way to communicate. It's all about identifying how they want to communicate, as opposed to saying you have to go to our website, you have to go to our store, you have to call us. Our whole thing is let's eliminate any barriers to communication and accessibility. We don't charge anything for our services. There's no fee. We provide free home delivery, all the support and education we do is free. We provide a whole collection of accessible packaging and accessible labeling, We make our money by being reimbursed by insurance companies to the patient. 25:52 …We want to package and label everything so that everyone in the household can understand what's behind the medicine cabinet. … We have individuals on staff who have macular degeneration, who have retinitis pigmentosa, who have diabetic retinopathy. It gives us credibility to be able to speak to a patient. It also gives us knowledge. …There's an enormous amount of people with macular degeneration who would benefit from our services. And a lot of groups, specifically healthcare groups and organizations know that if they have a patient who was diagnosed with macular degeneration, who is struggling, they refer them to us. Recommended Resources https://amdcentral.org https://www.evokekyne.com https://www.brightfocus.org http://www.mdsupport.org https://preventblindness.org https://www.macular.org http://www.supportsight.org http://www.mymacdlife.org https://vispero.com/mds * Note: All listed transcript timings and wording are approximations.Support this podcast at — https://redcircle.com/mymacdlife-macular-degeneration-podcast/donations

Danny Burstein is a seven- time Tony Award nominee for The Drowsy Chaperone, South Pacific, Follies, Golden Boy, Cabaret, and Fiddler on the Roof, who won a Best Supporting Actor in a Musical Tony in 2021 for his performance as Harold Zidler in the stage adaptation of Moulin Rouge! He has also won two Drama Desk Awards, four Outer Critics Circle Awards, and received three Grammy Award nominations. His other Broadway credits include The Seagull, Saint Joan, and Women on the Verge of a Nervous Breakdown. On television, Burstein appeared as different characters in six episodes of the original NBC drama series Law & Order and recurred as Lolly Steinman on the HBO series Boardwalk Empire. Other TV appearances include: Fosse/Verdon, The Good Fight, Evil, and Winning Time: The Rise of the Lakers Dynasty. Film roles include: Transamerica, Deception, The Family Fang, Nor'Easter, Blackhat, and Indignation. (Revised bio courtesy of BroadwayWorld.com)

In this episode, Courtenay welcomes Dr. David Burstein to the show to discuss his new (and first!) book, Smartphones Don't Give Hugs. Inspired by many thought leaders, and his own children, David provides insight into the anti-social agents produced by the digital era. The idea of being “connected” to many people on social media, yet close to none in real life, is affecting the mental health and overall well-being of many young teens. Emphasizing the quote “communication is the currency of social energy,” he talks about how this digital craze is impeding the upcoming generation's ability to communicate, emotionally regulate, take personal responsibility, and so much more. He further elaborates on how electronics emit dopamine, which essentially locks consumers into addiction, and how to restore one's quality of life. Ds Episode Resources: Limitless: Upgrade Your Brain, Learn Anything Faster, and Unlock Your Exceptional Life by Jim Kwik Nicholas Carr (author) The Israel Test by George Gilder Jordan Peterson (clinical psychologist) Andrew Huberman (neuroscientist) Tony Schwartz: The Energy Project  Connect with David: Buy the Book: Smartphones Don't Give Hugs https://www.amazon.com/Smartphones-Do-Not-Give-Hugs/dp/1778113915/iref=nodl_ ————————————————— Follow & Connect with Courtenay: https://www.courtenayturner.com Twitter: Courtenay Turner (@CourtenayTurner) :https://twitter.com/CourtenayTurner?s=20 Instagram: https://instagram.com/kineticcourtz?utm_medium=copy_link Read some of her articles: https://www.truthmatters.biz ————————————————— Other video Platforms: Rokfin: https://www.rokfin.com/courtenayturner Odysee: https://odysee.com/@CourtenayTurner:f Rumble: https://rumble.com/user/CourtenayTurner BitChute: https://www.bitchute.com/channel/yNVIxoBspPt6/ ————————————————— Video Edited By Griffo Productions www.griffoproductions.com ————————————————— ©2022 All Rights Reserved Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we are joined by Elizabeth Burstein, CEO, and Co-Founder of Neura Health, a virtual neurology clinic. Neura's mission is to improve the access and quality of neurological care: increase convenience, better outcomes, and lower costs. The platform connects patients to neurologists, with in-built neurology-specific symptom monitoring and condition-specific diagnostic tests. These include cognitive exams, psychomotor tests, and standard assessments. The platform also has HIPAA-compliant text messaging and video visits, with a care concierge service to help patients with their various needs. Tune in to learn more!